Biostaging of adenocarcinomas utilizing radiolabeled tumor-assoc

Details Biostaging of adenocarcinomas utilizing radiolabeled tumor-assoc Biostaging of adenocarcinomas utilizing radiolabeled tumor-assoc

1994-04-14

1996-01-09

Kamm, William E.

Surgery

Truss

Pad

128654, 424 149, 424 153, A61B 600

Patent

active

054820405

ABSTRACT:
Broadly, the present invention is directed to a method for reliably staging adenocarcinomas typified by colorectal cancer in patients who are undergoing surgery therefor. The method includes the administration of a radiolabeled tumor-associated glycoprotein (TAG) antibody (or other equivalent locator) to the cancer patient prior to surgical accession of the patient. Desirably, the present method includes surgical accession with a radiation detection probe for determining tissue exhibiting elevated levels of radiation. The preferred radiolabel is .sup.125 I, which is used to label an antibody specific to a high molecular weight glycoprotein called TAG-72. The preferred antibody is CC49, a murine monoclonal antibody of the IgG.sub.1 subclass. With radiolabeled monoclonal antibody CC49, it preferably is administered to the patient approximately 21 days (.+-.4 days) prior to surgery. Following surgical excision of all such tissue which is amenable to excision, the probe is again used to identify any remaining neoplastic tissue or tissue deposits, which may or may not be subjected to further excision attempts. After all possible excision of neoplastic tissue has occurred, final counts are taken with the probe to identify residual tissue deposits not excised. The number and location of the remaining tissue deposits form the basis of the biostaging system disclosed herein.

REFERENCES:
patent: 4361644 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4782840 (1988-11-01), Martin, Jr. et al.
patent: 4889991 (1989-12-01), Ramsey et al.
patent: 5008546 (1991-04-01), Mazziotta et al.
patent: 5171666 (1992-12-01), Gutowski et al.
patent: 5383456 (1995-01-01), Arnold et al.
Nieroda et al., Radioimmunoguided Surgery in Colorectal Cancer, 1991, V15,N3,P225-229.
Stella et al., Avidin-Biotin System in RIGS for Colorectal-Cancer, Apr. 1994,V37,N4,P335-343.
Hand et al., Potential for Recombinant Immunoglobulin Constructs . . . , Feb. 1994,V73,N3,P1105-1113.
Triozzi et al., Localization of . . . Lymph-node Lymphocytes using . . . Mab,Feb. 1994,V73,N3,P580-589.
Stella et al., Surgery for Colorectal Cancer Guided by Radiodetecting Probe . . . , 1991, V157,N8,P485-488.
Greiner et al., Applications for Mab and Recombinant Cytokines . . . , 1991,S2,P9-13.
Dawson et al., The Value of RIGS in 1st and 2nd Look Laparotomy for Cancer, 1991,V34,N3,P217-222.

Affiliated with

Also associated with

Rating

Biostaging of adenocarcinomas utilizing radiolabeled tumor-assoc does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biostaging of adenocarcinomas utilizing radiolabeled tumor-assoc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biostaging of adenocarcinomas utilizing radiolabeled tumor-assoc will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1296847